Bryan Tolliver to Humans
This is a "connection" page, showing publications Bryan Tolliver has written about Humans.
Connection Strength
0.307
-
Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. Addict Biol. 2022 01; 27(1):e13085.
Score: 0.029
-
A Multimethod Examination of Sensitivity to Reward and Sensitivity to Punishment in Bipolar Disorder and Alcohol Dependence: Results from a 2 ? 2 Factorial Design. Psychopathology. 2021; 54(2):70-77.
Score: 0.028
-
An evaluation of the impact of co-occurring anxiety and substance use disorder on bipolar disorder illness outcomes in STEP-BD. J Affect Disord. 2019 03 01; 246:794-799.
Score: 0.025
-
An item response theory evaluation of the young mania rating scale and the montgomery-asberg depression rating scale in the systematic treatment enhancement program for bipolar disorder (STEP-BD). J Affect Disord. 2016 Nov 15; 205:73-80.
Score: 0.021
-
Assessment and treatment of mood disorders in the context of substance abuse. Dialogues Clin Neurosci. 2015 Jun; 17(2):181-90.
Score: 0.019
-
Evidence for the continuous latent structure of mania and depression in out-patients with bipolar disorder: results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Psychol Med. 2015; 45(12):2595-603.
Score: 0.019
-
A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2012 Feb; 14(1):54-63.
Score: 0.015
-
Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. Alcohol Clin Exp Res. 2012 Mar; 36(3):490-6.
Score: 0.015
-
Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry Res. 2011 Aug 15; 188(3):361-5.
Score: 0.015
-
Predictors of clinical trial dropout in individuals with co-occurring bipolar disorder and alcohol dependence. Drug Alcohol Depend. 2011 Nov 01; 118(2-3):493-6.
Score: 0.014
-
Cognitive enhancers in the treatment of substance use disorders: clinical evidence. Pharmacol Biochem Behav. 2011 Aug; 99(2):285-94.
Score: 0.014
-
Determinants of cue-elicited craving and physiologic reactivity in methamphetamine-dependent subjects in the laboratory. Am J Drug Alcohol Abuse. 2010 Mar; 36(2):106-13.
Score: 0.013
-
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: a case series. J Clin Psychopharmacol. 2008 Aug; 28(4):464-7.
Score: 0.012
-
Treatment of patients comorbid for addiction and other psychiatric disorders. Curr Psychiatry Rep. 2007 Oct; 9(5):374-80.
Score: 0.011
-
Delay discounting and reward sensitivity in a 2 ? 2 study of bipolar disorder and alcohol dependence. Addiction. 2019 08; 114(8):1369-1378.
Score: 0.006
-
Identification and initial validation of empirically derived bipolar symptom states from a large longitudinal dataset: an application of hidden Markov modeling to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study. Psychol Med. 2019 05; 49(7):1102-1108.
Score: 0.006
-
Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence. Transl Psychiatry. 2017 07 04; 7(7):e1163.
Score: 0.006
-
Design and methods for the Better Resiliency Among Veterans and non-Veterans with Omega-3's (BRAVO) study: A double blind, placebo-controlled trial of omega-3 fatty acid supplementation among adult individuals at risk of suicide. Contemp Clin Trials. 2016 Mar; 47:325-33.
Score: 0.005
-
Does alexithymia explain variation in cue-elicited craving reported by methamphetamine-dependent individuals? Am J Addict. 2012 Mar-Apr; 21(2):130-5.
Score: 0.004
-
Impaired cognitive performance in subjects with methamphetamine dependence during exposure to neutral versus methamphetamine-related cues. Am J Drug Alcohol Abuse. 2012 May; 38(3):251-9.
Score: 0.004
-
The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina. Am J Addict. 2011 Sep-Oct; 20(5):447-55.
Score: 0.004
-
Independent predictors for lifetime and recent substance use disorders in patients with rapid-cycling bipolar disorder: focus on anxiety disorders. Am J Addict. 2010 Sep-Oct; 19(5):440-9.
Score: 0.003
-
Extinction of drug cue reactivity in methamphetamine-dependent individuals. Behav Res Ther. 2010 Sep; 48(9):860-5.
Score: 0.003
-
Correlates of historical suicide attempt in rapid-cycling bipolar disorder: a cross-sectional assessment. J Clin Psychiatry. 2009 Jul; 70(7):1032-40.
Score: 0.003
-
Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trials. J Clin Psychiatry. 2008 Jul; 69(7):1057-63.
Score: 0.003
-
Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. J Affect Disord. 2008 Sep; 110(1-2):167-73.
Score: 0.003
-
Uses of coercion in addiction treatment: clinical aspects. Am J Addict. 2008 Jan-Feb; 17(1):36-47.
Score: 0.003
-
Alcohol use and anxiety: diagnostic and management issues. Am J Psychiatry. 2007 Feb; 164(2):217-21; quiz 372.
Score: 0.003